The project aims to describe and compare the outcome of 12 weeks of prospective, randomized
treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle,
liver and adipose tissue, abdominal fat mass, total body and fat-free mass, efficacy for
symptoms of aggression and non-metabolic adverse events. Children aged 6-18 will be studied,
exploring effects of stimulant therapy and age-related differences in vulnerability to
treatment-induced adverse metabolic changes. Aims are addressed by measuring glucose and
lipid kinetics with stable isotope tracers, body composition with dual energy x-ray
absorptiometry and magnetic resonance imaging (MRI), and standardized assessments of efficacy
and adverse events. Relevant data are critically needed to target clinical therapy and basic
research, identify medical risks, and guide regulatory decisions in this vulnerable
population.
Phase:
Phase 4
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
National Institute of Mental Health (NIMH) National Institutes of Health (NIH)